+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID02823366

Evaluating Fenofibrate Plus Ursodeoxycholic Acid Versus Ursodeoxycholic Acid Alone for Primary Biliary Cirrhosis Patients with Inadequate Response to UDCA

Led by Xijing Hospital of Digestive Diseases · Updated on 2026-10-30

104

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the addition of fenofibrate to ursodeoxycholic acid UDCA treatment for patients with Primary Biliary Cirrhosis PBC who do not respond adequately to UDCA alone. PBC patients treated long-term with UDCA typically see improved liver blood tests and better survival without needing liver transplantation, but about 40% do not achieve a complete biochemical response and are at higher risk of disease progression. This Phase 3 clinical trial aims to explore whether fenofibrate can improve outcomes in these patients by potentially reducing bile acid production, enhancing bile secretion, and reducing inflammation. Participants are randomly assigned to one of two groups one receiving fenofibrate combined with UDCA, and the other continuing UDCA alone. The study will track changes in liver function and disease progression over 48 weeks. Key assessments include liver biopsies, liver stiffness measured by magnetic resonance elastography, and monitoring of various blood markers such as alkaline phosphatase, bilirubin, and transaminase levels at multiple time points during the study. During the trial, participants will have regular visits for blood tests and imaging at baseline, 4, 8, 12, 24, and 48 weeks to assess liver function and disease status. The primary outcome is the rate of patients achieving a complete biochemical response by week 24. Secondary outcomes include changes in liver biopsy results, risk scores, liver stiffness, and blood markers at week 48. The study is led by Xijing Hospital of Digestive Diseases and is expected to complete by December 2028.

CONDITIONS

Brief Title

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Research Team

Y

Ying Han, Ph.D

Y

Yongquan Shi, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here